7. In addition to patent waivers, should copyright also be subject to a waiver from TRIPS obligations, namely for the purpose of access to scientific works related to battling COVID-19? Further, under Article 39 of the TRIPS Agreement, should confidential information be subject to compulsory licensing as well, especially in the context of Article 40 of the TRIPS Agreement? Note that clinical trial test data is submitted to public authorities and is also (partially)

subject to confidentiality.